What are Incyte's total assets?

Incyte (INCY) holds $7.3B in total assets, up 27.7% year over year.

How much debt does Incyte have?

Incyte carries $39.4M in total debt against $5.6B of shareholders' equity, a debt-to-equity ratio of 0.01.

How much cash does Incyte have?

Incyte holds $3.5B in cash and equivalents.

Can Incyte cover its short-term obligations?

Its current ratio is 3.68 — current assets exceed current liabilities.

Where does Incyte's balance sheet data come from?

Every line is extracted from Incyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Incyte INCY Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$3.1B+83.5%	$1.69B-47.5%	$3.22B+8.9%	$2.95B+43.4%
Restricted cash	$1.85M+14.2%	$1.62M-12.1%	$1.85M+8.7%	$1.7M-1.3%
Accounts receivable, net	$1.02B+20.1%	$853.15M+14.7%	$743.56M+15.3%	$644.88M+4.6%
Inventories	$342.23M-1.7%	$348.33M+68.3%	$206.97M+162%	$78.96M+172%
Raw materials	$27.86M+1.0%	$27.59M+18.5%	$23.28M-27.0%	$31.87M+2,400%
Work in process	$343.68M+3.8%	$331.18M+57.9%	$209.79M+285%	$54.46M+36.5%
Finished goods	$71.75M+48.2%	$48.43M+31.4%	$36.86M+6.4%	$34.63M+120%
Prepaid expenses and other current assets	$317.83M+88.2%	$168.91M-7.6%	$182.83M+9.5%	$167.01M+32.3%
Trading assets	——	——	——	——
Total current assets	$5.02B+55.1%	$3.24B-30.3%	$4.65B+13.5%	$4.09B+31.2%
Property and equipment, net	$730.89M-4.3%	$763.41M+1.6%	$751.51M+1.7%	$739.31M+2.1%
Accumulated depreciation	$375.07M+14.4%	$327.98M+21.5%	$269.93M+26.8%	$212.81M+21.1%
Operating lease right-of-use assets	$27.52M-10.7%	$30.8M+20.6%	$25.54M-2.9%	$26.3M-4.5%
Goodwill	$133M-14.5%	$155.59M0.0%	$155.59M0.0%	$155.59M0.0%
Intangible assets, net	$117.13M+2.9%	$113.8M-7.9%	$123.55M-4.4%	$129.22M-14.3%
Other non-current assets	$18.17M+67.5%	$10.85M-79.2%	$52.11M+105%	$25.44M-31.8%
Available-for-sale securities	——	——	——	——
Total investments	$47.99M+155%	$18.81M-90.0%	$187.72M—	——
Allowance for credit losses	$0—	$0—	$0—	$0—
Total assets	$6.96B+27.8%	$5.44B-19.7%	$6.78B+16.1%	$5.84B+18.4%
Accounts payable	$209.94M+6.3%	$197.47M+80.2%	$109.6M-60.5%	$277.55M+61.3%
Accrued expenses	$228.07M+20.9%	$188.68M+23.0%	$153.35M+10.5%	$138.76M+27.3%
Current portion of long-term debt	$4.52M+2.2%	$4.42M+28.5%	$3.44M+8.2%	$3.18M+20.6%
Operating lease liabilities, current	$5.7M+2.0%	$5.58M-1.8%	$5.69M-30.6%	$8.2M-22.4%
Finance Lease Liability, Current	$4.52M+2.2%	$4.42M+28.5%	$3.44M+8.2%	$3.18M+20.6%
Income taxes payable	$4.76M-80.0%	$23.78M-43.8%	$42.3M—	——
Total current liabilities	$1.52B-7.7%	$1.64B+32.4%	$1.24B+7.2%	$1.16B+35.4%
Finance lease liabilities	$30.2M-10.0%	$33.54M+15.0%	$29.16M-3.1%	$30.08M-4.9%
Other non-current liabilities	$165.27M-1.4%	$167.54M+12.3%	$149.15M+50.3%	$99.24M+40.9%
Total liabilities	$1.79B-10.3%	$2B+25.4%	$1.59B+8.3%	$1.47B+26.4%
Preferred stock	$0—	$0—	$0—	$0—
Common stock	400M+207,154%	193K-13.8%	224K+0.4%	223K+0.9%
Additional paid-in capital	$4.93B+8.7%	$4.53B-9.6%	$5.02B+4.7%	$4.79B+4.9%
Retained earnings	$213.77M+120%	-$1.07B-769%	$160.39M+137%	-$437.21M+43.8%
Accumulated other comprehensive income (loss)	$25.46M+294%	-$13.12M-200%	$13.11M-13.0%	$15.07M+177%
Total stockholders' equity	$5.17B+49.9%	$3.45B-33.6%	$5.19B+18.8%	$4.37B+15.9%
Total liabilities and stockholders' equity	$6.96B+27.8%	$5.44B-19.7%	$6.78B+16.1%	$5.84B+18.4%
Available-for-Sale Debt Securities	$482.79M+2.7%	$470.26M+6.2%	$442.67M—	——
Debt securities - current	$482.79M+2.7%	$470.26M+6.2%	$442.67M—	——
Finished goods	$71.75M+48.2%	$48.43M+31.4%	$36.86M+6.4%	$34.63M+120%
Deferred Tax Assets and Other Non-Current Assets	$18.17M+67.5%	$10.85M-79.2%	$52.11M+105%	$25.44M-31.8%
Equity Securities (FV-NI) - Non-Current	$47.99M+155%	$18.81M-90.0%	$187.72M—	——
Equity Securities (Non-Current)	$47.99M+155%	$18.81M-90.0%	$187.72M—	——
Deferred tax assets	$515.29M-32.4%	$762.07M+20.6%	$631.89M+38.0%	$457.94M-2.1%
Other non-current assets	$18.17M+67.5%	$10.85M-79.2%	$52.11M+105%	$25.44M-31.8%
Other Intangible Assets Net	$117.13M+2.9%	$113.8M-7.9%	$123.55M-4.4%	$129.22M-14.3%
Property, plant and equipment at cost	$1.11B+1.3%	$1.09B+6.8%	$1.02B+7.3%	$952.12M+5.8%
Software and Technology Licenses, Net	$18.17M+67.5%	$10.85M-79.2%	$52.11M+105%	$25.44M-31.8%
Accrued Manufacturing Costs	$228.07M+20.9%	$188.68M+23.0%	$153.35M+10.5%	$138.76M+27.3%
Accrued Marketing and Advertising Expenses	$71.25M+113%	$33.44M-10.5%	$37.37M+20.0%	$31.15M-12.9%
Accrued Royalties (Current)	$40.68M-92.2%	$519.88M+34.2%	$387.36M+47.0%	$263.47M+56.4%
Other Commercial Liabilities	$1.03B-14.9%	$1.21B+29.6%	$935.57M+33.5%	$701.05M+31.4%
Accrued Income Taxes, Current	$4.76M-80.0%	$23.78M-43.8%	$42.3M—	——
Accrued Liabilities, Current	$1.03B-14.9%	$1.21B+29.6%	$935.57M+33.5%	$701.05M+31.4%
Compensation and benefits	$228.07M+20.9%	$188.68M+23.0%	$153.35M+10.5%	$138.76M+27.3%
Other accrued liabilities	$90.72M+54.1%	$58.87M-19.7%	$73.33M+1.8%	$72.05M+57.5%
Contingent Consideration Liability (Non-Current)	$79.86M-48.1%	$153.76M-11.4%	$173.58M-5.9%	$184.46M-10.9%
Marketing and selling	$71.25M+113%	$33.44M-10.5%	$37.37M+20.0%	$31.15M-12.9%
Common Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Common Stock Shares Issued	198.5M+2.6%	193.4M-13.8%	224.3M+0.7%	222.7M+0.8%
Convertible Preferred Stock Authorized Shares	5M0.0%	5M0.0%	5M0.0%	5M0.0%
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—
Additional paid-in capital	$4.93B+8.7%	$4.53B-9.6%	$5.02B+4.7%	$4.79B+4.9%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$198K+2.6%	$193K-13.8%	$224K+0.4%	$223K+0.9%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—
Preferred Stock Par Value Per Share	$0.000.0%	$0.000.0%	$0.000.0%	$0.000.0%
Share-Based Payment Award Options Outstanding - Number	9.3M+7.1%	8.7M+20.8%	7.2M+38.1%	5.2M+30.8%
Share-Based Payment - Unrecognized Cost of Nonvested Awards	$66.86-1.4%	$67.81-6.0%	$72.17—	——
Shares Reserved for Future Issuance Under Stock Plans	9.1M+126%	4M-62.9%	10.8M+114%	5.1M-50.0%
Cumulative Cost Basis	$1.11B+1.3%	$1.09B+6.8%	$1.02B+7.3%	$952.12M+5.8%
Expected Pension Contributions	——	——	——	——
Accounts Receivable, after Allowance for Credit Loss	$1.02B+20.1%	$853.15M+14.7%	$743.56M+15.3%	$644.88M+4.6%
Clinical related costs	$175.93M+32.8%	$132.45M+20.8%	$109.62M-16.0%	$130.57M+19.3%
Licensing Arrangements	$40.68M-92.2%	$519.88M+34.2%	$387.36M+47.0%	$263.47M+56.4%
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five	——	——	——	——
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One	——	——	——	——
Common stock, par value (in dollars per share)	$00.0%	$00.0%	$00.0%	$00.0%
Common stock, shares authorized (in shares)	$400M0.0%	$400M0.0%	$400M0.0%	$400M0.0%
Common stock, shares issued (in shares)	$198.46M+2.6%	$193.43M-13.8%	$224.29M+0.7%	$222.75M+0.8%
Common Stock, Shares, Outstanding	$198.46M+2.6%	$193.43M-13.8%	$224.29M+0.7%	$222.75M+0.8%
Debt Securities, Available-for-Sale, Allowance for Credit Loss	$0—	$0—	$0—	$0—
Investments	$480.79M+2.3%	$469.92M—	——	——
Estimated Fair Value	——	——	——	——
Defined Benefit Plan Expected Future Employer Contributions Current Fiscal Year	——	——	——	——
Current maturities of long-term debt	$4.52M+2.2%	$4.42M+28.5%	$3.44M+8.2%	$3.18M+20.6%
Finance Lease, Right-of-Use Asset, after Accumulated Amortization	$27.52M-10.7%	$30.8M+20.6%	$25.54M-2.9%	$26.3M-4.5%
Inventory Net Current and Noncurrent	$443.29M+8.9%	$407.2M+50.8%	$269.94M+123%	$120.96M+112%
Inventory incurred prior to FDA approval	——	——	——	——
Preferred Stock, Par or Stated Value Per Share	$00.0%	$00.0%	$00.0%	$00.0%
Preferred Stock, Shares Authorized	$5M0.0%	$5M0.0%	$5M0.0%	$5M0.0%
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—
Provision for contract loss	$642.47M+46.7%	$438.05M+56.5%	$279.91M+45.7%	$192.13M+40.7%
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value	$66.86-1.4%	$67.81-6.0%	$72.17—	——
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number	$9.28M+7.1%	$8.66M+20.8%	$7.17M+38.1%	$5.19M+30.8%
Incentive stock program, shares reserved for future grants (in shares)	$9.06M+126%	$4.01M-62.9%	$10.82M+114%	$5.06M-50.0%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Incyte.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Incyte's total assets?: Incyte (INCY) holds $7.3B in total assets, up 27.7% year over year.
How much debt does Incyte have?: Incyte carries $39.4M in total debt against $5.6B of shareholders' equity, a debt-to-equity ratio of 0.01.
How much cash does Incyte have?: Incyte holds $3.5B in cash and equivalents.
Can Incyte cover its short-term obligations?: Its current ratio is 3.68 — current assets exceed current liabilities.
Where does Incyte's balance sheet data come from?: Every line is extracted from Incyte's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.